Get the Stockscreener App
182.28
1.86%
3.32
Pre-market:
182.73
0.45
+0.25%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $182.28, with a volume of 1.74M.
It is up +1.86% in the last 24 hours and up +0.23% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$178.96
Open:
$181.36
24h Volume:
1.74M
Relative Volume:
0.91
Market Cap:
$282.69B
Revenue:
$60.48B
Net Income/Loss:
$10.40B
P/E Ratio:
54.74
EPS:
3.3297
Net Cash Flow:
$8.05B
1W Performance:
+0.26%
1M Performance:
+0.23%
6M Performance:
+101.88%
1Y Performance:
+147.19%
1-Day Range:
$180.39
$183.67
1-Week Range:
$177.88
$186.12
52-Week Range:
$68.61
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
182.28 | 282.69B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,160.95 | 1.04T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
238.33 | 573.71B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
224.77 | 397.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.76 | 298.26B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.92 | 293.69B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
AstraZeneca PLC (AZN) Presents at American Diabetes Association (ADA) 86th Scientific SessionsSlideshow - Seeking Alpha
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know - Yahoo Finance Singapore
AstraZeneca PLC Stock (US6549022043): Obesity Drug Elecoglipron Heads Into Phase 3 As Shares Climb - AD HOC NEWS
ASTRAZENECA : Deutsche Bank maintains a Sell rating - marketscreener.com
ADA 2026: AstraZeneca To Move Fast On Obesity And Heart Pill Combinations - Citeline News & Insights
Jim Cramer on AstraZeneca: “On Track to Hit the Ambitious Long-Term Financial Targets” - Yahoo Finance
Hansa Biopharma appoints Head of Business Development from AstraZeneca - marketscreener.com
AstraZeneca advances oral GLP-1 elecoglipron into phase 3 - MSN
AstraZeneca PLC stock (US6549022043): obesity drug data and pipeline momentum keep investors alert - AD HOC NEWS
AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials - Benzinga
Functional genomics and AI drive novel target discovery at AstraZeneca - Select Science
ASTRAZENECA : JP Morgan remains its Buy rating - marketscreener.com
ADA26: AstraZeneca unveils positive data for Phase III-ready oral GLP-1RA - Clinical Trials Arena
MitoRx Therapeutics Strengthens Leadership Team with C-Suite and Board Appointments to Support Next Phase of Growth - GlobeNewswire Inc.
AstraZeneca Advances Obesity, Diabetes Medication Elecoglipron to Phase 3 Trial - marketscreener.com
ASTRAZENECA : Deutsche Bank reiterates its Sell rating - marketscreener.com
NYLIM VP Income Builder Portfolio's AstraZeneca PLC(AZN) Holding History - GuruFocus
BofA reiterates Buy on AstraZeneca stock, cites adjuvant trial outlook By Investing.com - Investing.com South Africa
AstraZeneca progresses elecoglipron after positive phase IIb results - London South East
Why is CAMBRIA-1 emerging as AstraZeneca’s key breast cancer catalyst? - Investing.com Nigeria
ASTRAZENECA : Jefferies remains its Buy rating - marketscreener.com
AstraZeneca Gears Up for Phase 3 Trial of Weight-loss Drug - marketscreener.com
IAMS WEALTH MANAGEMENT, LLC's AstraZeneca PLC(AZN) Holding History - GuruFocus
AstraZeneca (AZN) Advances Elecoglipron to Phase 3 Trials After Positive Results - GuruFocus
Elecoglipron cut nearly 12% of body weight in study, AstraZeneca says - AOL.com
AstraZeneca unveils data behind Phase III-bound oral GLP-1 - FirstWord Pharma
AstraZeneca’s oral GLP-1 advances to Phase III after strong trial results - Investing.com Nigeria
AstraZeneca obesity pill shows 10.5% weight loss in trial By Investing.com - Investing.com UK
AstraZeneca : Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfolio - marketscreener.com
AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial - marketscreener.com
AstraZeneca advances weight-loss pill to take aim at obesity leaders - Financial Times
ADA 2026: AstraZeneca Advances Oral GLP-1 Elecoglipron Into Phase III After Positive Trial Data - Citeline News & Insights
AstraZeneca plc stock (GB0009895292): Oncology pipeline, obesity push and latest trial updates in fo - AD HOC NEWS
AZN Stock Quote Price and Forecast - CNN
AstraZeneca PLC (AZN) Stock Analysis: Robust Revenue Growth and a 20.73% Upside Potential - DirectorsTalk Interviews
AstraZeneca hails phase 3 trial results of inhibitor Ultomiris - London South East
AstraZeneca | Pharmaceuticals, Vaccines, & Facts | Britannica Money - Britannica
AstraZeneca warns it could delay Europe drug launchesFT - marketscreener.com
PRESS: AstraZeneca warns it could delay Europe drug launchesFT - London South East
AstraZeneca chief warns group could withhold new drugs in Europe - Financial Times
AstraZeneca Broadens US Growth Push - marketscreener.com
AstraZeneca advances Friday, outperforms market - MarketWatch
AstraZeneca plc stock (GB0009895292): Share price edges higher after 3.1% move and valuation focus - AD HOC NEWS
AstraZeneca (AZN) Stock Gains 3.1% as Bernstein Highlights Overlooked Non-Oncology Potential - parameter.io
AstraZeneca (AZN) Stock: Bernstein's £186 Target Highlights Overlooked Non-Oncology Potential - MoneyCheck
AstraZeneca (AZN) Stock: Bernstein Identifies 37% Upside Potential in Overlooked Segment - Blockonomi
AstraZeneca (AZN) Stock: Bernstein Sees 37% Upside as Non-Oncology Gets Ignored - CoinCentral
NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History - Yahoo Finance
Bernstein: Why AstraZeneca’s biggest growth opportunity is being overlooked By Investing.com - Investing.com Nigeria
Worldwide Healthcare Trust outperforms benchmark; praises AstraZeneca - marketscreener.com
Why is AstraZeneca trending right now - Kalkine Media
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.92%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):